Candida en la cavidad oral de pacientes con VIH en Cali, Colombia: determinación de especies y sensibilidad al fluconazol

Luz Ángela Castro; María Inés Álvarez; Ernesto Martínez

doi:10.17533/udea.iatreia.v28n4a02

Authors

Luz Ángela Castro Valle University
María Inés Álvarez Valle University
Ernesto Martínez Valle University. Evaristo Garcia Valle University Hospital

DOI:

https://doi.org/10.17533/udea.iatreia.v28n4a02

Keywords:

candida, CD4 lymphocyte count , fluconazole, HIV, oral cavity

Abstract

Introduction: Candida albicans is the most frequently isolated yeast from the oral cavity of HIV-infected individuals. The use of fluconazole has increased the
number of resistant or less-sensitive Candida species different from C. albicans, to this antifungal agent.

Objective: To establish the Candida species present in the oral cavity of HIV-infected individuals at a hospital in Cali (Colombia), their population densities, and the susceptibility to fluconazole of species different from C. albicans.

Materials and methods: Samples were cultured in CHROMagar Candida and the number of colony forming units (CFU) was counted. Yeast identification was done with API 20C Aux, and the susceptibility
tests to fluconazole, by Etest.

Results: 230 patients were studied, and 202 isolates were obtained: 106 single and 96 mixed. C. albicans predominated, followed by C. dubliniensis and C.
glabrata. Candida species other than C. albicans predominated in counts lower than 400 CFU/mL. Susceptibility study to fluconazole of species different from
C. albicans showed that 14 (40 %) of the isolates were susceptible dose-dependent and 7 (20 %), resistant.

Conclusion: In the studied population, the oral cavity was colonized by non-wild type isolates that represent a risk for the development of oropharyngeal candidiasis resistant to fluconazole treatment.

|Abstract

= 557 veces | PDF (ESPAÑOL (ESPAÑA))

= 301 veces|

Downloads

Download data is not yet available.

Author Biographies

Luz Ángela Castro, Valle University

Associate Professor, School of Bacteriology and Clinical Laboratory, Valle University, Cali, Colombia.

María Inés Álvarez, Valle University

Professor Associado, Departamento de Microbiologia, Valle University, Cali, Colômbia.

Ernesto Martínez, Valle University. Evaristo Garcia Valle University Hospital

Assistant Professor, Department of Internal Medicine, Valle University. Infectious disease specialist, Evaristo Garcia Valle University Hospital, Cali, Colombia.

References

(1.) Ruhnke M. Skin and mucous membrane infections. In: Calderone RA, editor. Candida and Candidiasis. 2a ed. Washington: ASM Press; 2002. p. 307-25.

(2.) Li X, Lei L, Tan D, Jiang L, Zeng X, Dan H, et al. Oropharyngeal Candida colonization in human immunodeficiency virus infected patients. APMIS. 2013 May;121(5):375-402.

(3.) Nweze EI, Ogbonnaya UL. Oral Candida isolates among HIV-infected subjects in Nigeria. J Microbiol Immunol Infect. 2011 Jun;44(3):172-7.

(4.) Walmsley S, King S, McGeer A, Ye Y, Richardson S. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis. 2001 Jun;32(11):1554-61.

(5.) Zhu HW, McMillan AS, McGrath C, Li LS, Samaranayake LP. Oral carriage of yeasts and coliforms in stroke sufferers: a prospective longitudinal study. Oral Dis. 2008 Jan;14(1):60-6.

(6.) Epstein JB, Pearsall NN, Truelove EL. Quantitative relationships between Candida albicans in saliva and the clinical status of human subjects. J Clin Microbiol. 1980 Sep;12(3):475-6.

(7.) Erköse G, Erturan Z. Oral Candida colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4+Tlymphocyte count. Mycoses. 2007 Nov;50(6):485-90.

(8.) Luque AG, Biasoli MS, Tosello ME, Binolfi A, Lupo S, Magaró HM. Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina. Mycoses. 2009 Jan;52(1):53-9.

(9.) Gutiérrez C, De Bedout C, Tobón AM, Cano LE, Arango M, Tabares AM, et al. Sensibilidad a fluconazol y voriconazol de aislamiento de Candida spp., obtenidos de aislamientos de mucosa oral de pacientes con sida. Infectio. 2007;11(4):183-9.

(10.) Mendoza N, Arora A, Motta A, Arias C. Prevalence of oral candidiasis in the HAART era in developing countries: A cohort from Colombia. J Am Acad Dermatol. 2008;58(2 Suppl 2):AB94.

(11.) Castro LÁ, Álvarez MI, Martínez E. Pseudomembranous candidiasis in HIV/AIDS patients in Cali, Colombia. Mycopathologia. 2013 Feb;175(1-2):91-8.

(12.) Hospenthal DR, Murray CK, Beckius ML, Green JA, Dooley DP. Persistence of pigment production by yeast isolates grown on CHROMagar Candida medium. J Clin Microbiol. 2002 Dec;40(12):4768-70.

(13.) Loreto ES, Scheid LA, Nogueira CW, Zeni G, Santurio JM, Alves SH. Candida dubliniensis: epidemiology and phenotypic methods for identification. Mycopathologia. 2010 Jun;169(6):431-43.

(14.) Clinical and Laboratory Standards Institute. M27-S4. Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI. 2012 Dec; 32 Suppl 4:1-23.

(15.) Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, et al. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2014 Apr;58(4):2006-12.

(16.) Gugnani HC, Becker K, Fegeler W, Basu S, Chattopadhya D, Baveja U, et al. Oropharyngeal carriage of Candida species in HIV-infected patients in India. Mycoses. 2003 Sep;46(8):299-306.

(17.) Samaranayake LP, MacFarlane TW, Lamey PJ, Ferguson MM. A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol. 1986 Aug;15(7):386-8.

(18.) Masiá Canuto M, Gutiérrez Rodero F, Ortiz de la Tabla Ducasse V, Hernández Aguado I, Martín González C, Sánchez Sevillano A, et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2000 Aug;19(8):593-601.

(19.) Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia. 2012 Oct;174(4):259-71.

(20.) Hamza OJ, Matee MI, Moshi MJ, Simon EN, Mugusi F, Mikx FH, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol. 2008 Aug;8:135.

(21.) Baradkar VP, Kumar S. Species identification of Candida isolates obtained from oral lesions of HIV infected patients. Indian J Dermatol. 2009 Oct-Dec ;54(4):385-6.

(22.) Katiraee F, Khosravi AR, Khalaj V, Hajiabdolbaghi M, Khaksar A, Rasoolinejad M, et al. Oropharyngeal candidiasis and oral yeast colonization in Iranian human immunodeficiency virus positive patients. J Mycol Méd. 2010 Mar;20(1):8-14.

(23.) Coleman DC, Sullivan DJ, Bennett DE, Moran GP, Barry HJ, Shanley DB. Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS. 1997 Apr;11(5):557-67.

(24.) Chunchanur SK, Nadgir SD, Halesh LH, Patil BS, Kausar Y, Chandrasekhar MR. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients. Indian J Pathol Microbiol. 2009 Oct-Dec;52(4):501-4.

(25.) Suárez BL, Alvarez MI, de Bernal M, Collazos A. Candida species and other yeasts in the oral cavities of type 2 diabetic patients in Cali, Colombia. Colomb Méd. 2013 Mar;44(1):26-30.

(26.) Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. JDR. 2007 Mar;86(3):204-15.

(27.) Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol. 2002 Feb;40(2):341-50.

(28.) Giammanco GM, Pecorella S, Distefano S, Pecoraro V, Milici ME, Pizzo G. Fluconazole susceptibility of Italian Candida dubliniensis clinical isolates determined by reference and simplified tests. New Microbiol. 2001 Oct;24(4):397-404.

(29.) Pinjon E, Moran GP, Jackson CJ, Kelly SL, Sanglard D, Coleman DC, et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother. 2003 Aug;47(8):2424-37.

(30.) Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB, et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother. 1997 Mar;41(3):617-23.

(31.) Moris DV, Melhem MS, Martins MA, Souza LR, Kacew S, Szeszs MW, et al. Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals. J Med Microbiol. 2012 Dec;61(Pt 12):1758-65.

(32.) Jang MJ, Shin JH, Lee WG, Kim MN, Lee K, Lee HS, et al. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values. Ann Lab Med. 2013 May;33(3):167-73.

(33.) Rodriguez Costa C, Aquino de Lemos J, Sena Passos X, Rodriguez de Araújo C, Cohen AJ, Hasimoto e Souza LK, et al. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia. 2006 Jul;162(1):45-50.

(34.) Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006 Oct;44(10):3551-6.